Risk Factors for Chronic Postoperative Pain After Elective Nephrectomy
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Nov 2, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risk factors that can lead to chronic pain after a type of surgery called elective nephrectomy, which involves removing a kidney. The goal is to understand how much pain patients experience at different times after the surgery—specifically, one hour, three months, and one year later. To measure this pain, researchers will use a simple scale from 0 (no pain) to 10 (worst pain imaginable). By identifying patients who might be at higher risk for chronic pain, the study aims to find ways to help reduce this pain and improve overall recovery.
To participate in this trial, patients need to be between 18 and 90 years old and undergoing elective nephrectomy while receiving general anesthesia. The study will include a range of patients, regardless of gender, but will exclude anyone who cannot be contacted after the surgery or who passes away within a year. If you join the study, you can expect to share your pain experiences at the specified times, and this information will help researchers learn more about managing pain after surgery.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: -Patients aged 18-90 years,
- • ASA I-IV,
- • undergoing elective nephrectomy under general anesthesia will be included in the study.
- Exclusion Criteria:
- • Patients who cannot be reached by phone and hose who die within the 1-year postoperative period will be excluded from the study.
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Aylin Nizamoglu, Doctor
Study Director
Istanbul Univerisity-Cerrahpasa Cerrahpasa Faculty of Medicine
Safak E Erbabacan, associate professor
Study Chair
Istanbul Univerisity-Cerrahpasa Cerrahpasa Faculty of Medicine
Fatis Altindas, Professor
Study Chair
Istanbul Univerisity-Cerrahpasa Cerrahpasa Faculty of Medicine
Ilayda Bilgili Altuntas, Physician
Principal Investigator
Istanbul Univerisity-Cerrahpasa Cerrahpasa Faculty of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported